RAFAEL HLDGS B DL-,01

Rafael Holdings has completed patient recruitment for the pivotal phase-3 trial TransportNPC with 94 patients at 27 sites in 13 countries; an additional 10 patients were enrolled in a single-arm pediatric substudy. The company expects topline results for the main cohort in the second half of calendar year 2026 and, following a completed pre-NDA meeting, aims to file a marketing application in H2 2026. Data from the pediatric substudy showed improvement or stabilization in 80% of patients without drug-related serious adverse events, and the Expanded Access Program may continue. Investors reacted positively: the stock rose sharply and is currently trading at $1.93. » Plus sur de.investing.com

Rafael Holdings said its subsidiary Cyclo Therapeutics has obtained an exclusive license from MIT for a U.S. patent covering the use of cyclodextrins in Alzheimer’s patients with the ApoE4 mutation. The license strengthens the IP portfolio for the drug candidate Trapsol Cyclo; preclinical data show improved cholesterol transport, reduced tau pathology and better learning and memory performance in mice. Rafael has a market capitalization of $66.58 million and was not profitable last year, although cash exceeds debt. Trapsol Cyclo is also being studied in clinical trials for Niemann‑Pick disease type C1, with phase‑3 results expected in Q3 2026. » Plus sur de.investing.com

Rafael Holdings has issued 1,078,796 warrants entitling holders to subscribe for a total of 380,253 class B common shares. The warrants arose from the automatic conversion of Cyclo Therapeutics warrants during the merger process and are tradable under the ticker RFL-WT on the NYSE American. Each warrant entitles the holder to approximately 0.3525 class B shares at an exercise price of USD 14.19; the exercise period ends on December 11, 2025 at 5:00 p.m. EST. » Plus sur de.investing.com